Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 13/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 13/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043474 | 0.75 | OPRL1 (0.50) | CARM1 | |
| SCHEMBL1044103 | 0.74 | CARM1 (0.40) | PRMT5WDR77CARM1ALDH1A1 | |
| SCHEMBL1045644 | 0.74 | CARM1 (0.44) | PRMT5WDR77IDO1CARM1 | |
| SCHEMBL1044565 | 0.74 | MEN1 (0.44) | IDO1ALDH1A1MAPT | |
| SCHEMBL1044104 | 0.74 | LMNA (0.41) | IDO1 | |
| SCHEMBL6526308 | 0.73 | ALDH1A1 (0.38) | PRMT5WDR77IDO1ALDH1A1RECQL | |
| SCHEMBL8990452 | 0.69 | TSHR (0.43) | IDO1CARM1ALDH1A1 | |
| SCHEMBL16256343 | 0.68 | IDO1 (0.32) | IDO1 | |
| SCHEMBL9998995 | 0.68 | IDO1 (0.36) | IDO1ALDH1A1 | |
| SCHEMBL9998627 | 0.67 | MEN1 (0.35) | IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271613-B1 | HYDROXYMETHYLCYCLOHEXYLAMINES | GRUENENTHAL GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8288406-B2 | Hydroxymethylcyclohexylamines | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | Grünenthal GmbH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2271613-A1 | HYDROXYMETHYLCYCLOHEXYL AMINES | Grünenthal GmbH (DE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009118171-A1 | HYDROXYMETHYLCYCLOHEXYL AMINES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | OPRL1, OPRM1, OPRD1 | PRMT5 673/4885WDR77 628/4885IDO1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.